1-monooleoyl-rac-glycerol has been researched along with Periodontal-Diseases* in 2 studies
2 other study(ies) available for 1-monooleoyl-rac-glycerol and Periodontal-Diseases
Article | Year |
---|---|
Effect of ethylcellulose and propylene glycol on the controlled-release performance of glyceryl monooleate-mertronidazole periodontal gel.
Controlled-release metronidazole, mucoadhesive gel proposed as a drug-delivery system for periodontal application was developed and characterized. The system was based on a mixture of glycerylmonooleate (GMO) and ethylcellulose (EC). The mechanism of release depends: firstly, on the ability of GMO to form a viscous liquid crystalline mesophases and secondly on the solubilized EC to form a hydrophobic network when the mixture comes into contact with water resulting in sustaining the release of the drug. Ethylcellulose dissolved in GMO had a profound influence on the rate of drug release, reduced the initial drug release and prolonged the sustained release of metronidazole. Propylene glycol (PG) was added to increase the solubility of the drug and water was added with PG to control the viscosity. A controlled release formulation containing w/w, 20% metronidazole, 10% PG, 5% water and 65% GMO that contains 7% EC was found to be mucoadhesive, easily injectable at room temperature, and to follow Fickian diffusion release mechanism. When the drug loading was increased the drug release was accelerated, and the mechanism followed anomalous controlled-release mechanism. Stability studies indicated that the formulation should be stored at 4 °C in a dark place. Topics: Adhesiveness; Animals; Anti-Infective Agents; Cellulose; Chickens; Delayed-Action Preparations; Drug Delivery Systems; Drug Liberation; Drug Stability; Drug Storage; Excipients; Gels; Glycerides; Humans; Metronidazole; Mucous Membrane; Particle Size; Periodontal Diseases; Phase Transition; Propylene Glycol; Rheology; Solubility | 2015 |
Formulation of a drug delivery system based on a mixture of monoglycerides and triglycerides for use in the treatment of periodontal disease.
This paper describes the development of a stable, controlled-release formulation of metronidazole for use in the treatment of periodontal disease. It is formulated as a suspension, which undergoes transformation to a release-controlling, semi-solid on contact with gingival fluid. The system is based on the ability of mixtures of monoglycerides and triglycerides to form liquid crystals, i.e., reversed hexagonals, in contact with water. The reversed hexagonal form was found to have the most favourable sustained release properties, compared with those from the cubic form. The source of metronidazole is the prodrug, metronidazole benzoate, which further helps to slow down the release rate. Product characteristics are assessed by differential scanning calorimetry and viscometry. The release data derive from the results of in vitro dissolution tests. X-ray diffraction, phase diagrams, and polarized light microscopy were used to elucidate the structure of the liquid crystalline phases. Topics: Biodegradation, Environmental; Chemistry, Pharmaceutical; Crystallization; Delayed-Action Preparations; Diffusion; Drug Design; Drug Implants; Gels; Glycerides; Humans; Metronidazole; Periodontal Diseases; Sesame Oil; Solubility; Syringes; Temperature; Viscosity; X-Ray Diffraction | 1992 |